This Phase II trial is evaluating how safe and effective a targeted therapy (BNT111) is when used by itself or combined with immunotherapy (cemiplimab) in people with anti-PD1-refractory or relapsed melanoma.
This trial is treating patients with anti-PD1-refractory or relapsed unresectable stage III or IV melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
This is a randomised trial with three experimental arms. In Experimental Arm 1, participants will receive BNT111 (via intravenous injection) in combination with cemiplimab (via intravenous infusion). In Experimental Arm 2, participants will receive BNT111 by itself (via intravenous injection). In Experimental Arm 3, participants will receive cemiplimab by itself (via intravenous infusion).
Recruiting Hospitals Read More